Orthofix Medical Inc. (OFIX)

Orthofix Medical Inc.'s Q·Score is 6.3/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.5× debt-to-equity). Key area to monitor: currently unprofitable (-11% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for OFIX is $17.25, based on ratings from 4 Wall Street analysts. This is 44.8% above the current price of $11.91. Price targets are forward-looking estimates and not guarantees of future performance.

Orthofix Medical Inc. (OFIX) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 13.9×. The consensus analyst price target of $17.25 is 45% above the current price.

Orthofix Medical Inc. is scheduled to report earnings in 2 days, on May 5, 2026.

Orthofix Medical Inc. has a net profit margin of -11.2%, indicating the company is currently operating at a net loss. Its gross margin stands at 68.8%, indicating a high-margin business model.

Orthofix Medical Inc. is reporting modest revenue growth of 2.0%.

Orthofix Medical Inc. has a debt-to-equity ratio of 0.45×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 2.44×, indicating comfortable short-term liquidity.